Trovagene, Inc. (NASDAQ: Â TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.
“In 2013, we transitioned from a technology-driven company to one focused on building a body of clinical evidence, including health economic data, to demonstrate how our molecular diagnostic platform may change the way cancer patients are treated,†stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. “This year, we plan to release additional oncogene mutation assays to broaden the reach of our technology, and to present additional clinical study results to establish the value of our innovative platform.â€
Fourth Quarter 2013 Financial Results
For the fourth quarter ended December 31, 2013, Trovagene reported a net loss of $1.0 million, or $0.05 per share, as compared to a net loss of $6.3 million, or $0.43 per share, for the quarter ended December 31, 2012. The change in net loss is primarily due to an increase in total operating expenses of $1.3 million offset by a change in the fair value of derivative instruments related to warrants of $6.7 million, as compared to the prior year period.
Year End 2013 Financial Results
For the year ended December 31, 2013, Trovagene reported a net loss of $11.8 million or $0.70 per share, as compared to a net loss of $11.6 million, or $0.89 per share, for the twelve months ended December 31, 2012. The change in net loss is due primarily to an increase in total operating expenses of $5.6 million, offset by a change in the fair value of derivative instruments related to warrants of $5.6 million, as compared to the prior year period.
Cash and Cash Equivalents
Trovagene had cash and cash equivalents of $25.8 million as of December 31, 2013, as compared to $10.8 million on December 31, 2012. The Company completed a $15 million registered direct offering on July 31, 2013.
Summary of Corporate Events
Clinical Collaborations and Assay Development
Trovagene continues to advance its molecular diagnostic platform for the non-invasive monitoring of cancer patients. The Company currently has six ongoing clinical programs, with goals to establish the clinical utility of its oncogene mutation assays, demonstrate health economic benefits, and improve the overall standard-of-care for cancer treatment.
In 2013, Trovagene executed on the following:
- Expanded clinical collaboration with the University of Texas MD Anderson Cancer Center
- Validated and released BRAF V600E mutation monitoring test, the Company’s first urine-based oncogene assay, through Trovagene’s CLIA laboratory
- Entered into a clinical trial agreement with USC Norris Cancer Center to conduct a study evaluating genomic characterizations of metastatic colorectal cancers using Trovagene’s proprietary assay technology
- Presented early data from a clinical study with MD Anderson Cancer Center demonstrating  strong concordance between tissue biopsy and Trovagene’s molecular diagnostic platform for identifying mutational status, in addition to providing clinical evidence that urine-based assays can be useful for monitoring cancer treatment response over time
- Signed clinical study agreement with US Oncology Research to examine the utility of quantitative KRAS mutation detection and monitoring in metastatic pancreatic cancer patients
In the first quarter of 2014, the Company announced the following:
- Released first urine-based multiplexed oncogene mutation assay utilizing Next Generation Sequencing (NGS) technology, for the detection and monitoring of seven mutations in the KRAS oncogene
In addition to Trovagene’s focus on developing and commercializing its non-invasive molecular diagnostic platform for cancer monitoring, the Company is pursuing non-core corporate development activities including the following:
Collaborations with Pharmaceutical and Strategic Diagnostic and Life Science Companies